Evaluating the Impact of Fecal Microbiota Transplantation on Parkinson’s Disease
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on September 6th, 2024
|
Gut microbiota dysbiosis has been observed in patients with premotor symptoms of Parkinson’s disease and may accelerate disease progression. Previous animal studies have indicated that fecal microbiota transplantation (FMT) could offer neuroprotective benefits in Parkinson’s. A recent study published in the Journal of the American Medical Association investigated whether FMT could improve outcomes in Parkinson’s disease.
The study involved 45 participants with a median age of 65, all diagnosed with Parkinson’s disease exhibiting mild to moderate motor and nonmotor symptoms. Participants were randomly assigned to receive either a placebo or a single fecal microbiota transplantation, administered into the cecum via colonoscopy. Assessments conducted at 6 and 12 months post-treatment found no significant improvement in Parkinson’s symptoms, as measured by the MDS-UPDRS scale. The authors emphasized that this negative result may not be conclusive, noting that various factors in the preparation of fecal material—such as aerobic versus anaerobic conditions, cryoprotectant concentration, antibiotic pretreatment, and the method of administration—could influence outcomes. They suggested that future studies should consider these factors and also compare different forms of control treatments, such as an inert placebo versus autotransplantation.
The study involved 45 participants with a median age of 65, all diagnosed with Parkinson’s disease exhibiting mild to moderate motor and nonmotor symptoms. Participants were randomly assigned to receive either a placebo or a single fecal microbiota transplantation, administered into the cecum via colonoscopy. Assessments conducted at 6 and 12 months post-treatment found no significant improvement in Parkinson’s symptoms, as measured by the MDS-UPDRS scale. The authors emphasized that this negative result may not be conclusive, noting that various factors in the preparation of fecal material—such as aerobic versus anaerobic conditions, cryoprotectant concentration, antibiotic pretreatment, and the method of administration—could influence outcomes. They suggested that future studies should consider these factors and also compare different forms of control treatments, such as an inert placebo versus autotransplantation.